33 results about "Hyperammonemia" patented technology

The present disclosure relates to a bio-sensor capable of measuring the total concentration of one or a plurality of ammonia or ammonium ions with the use of indophenol reagents in the presence of an ionomer. In some embodiments, the biosensor comprises a perflurinated membrane that comprises an ionomer in contact with an alkaline buffer in a vessel configured to receive a sample, such as whole blood. The disclosure also relates to a method of detecting or quantifying the ammonia or ammonium ion concentration in whole blood in a point of care biosensor without reliance on gas chromatography or any measurement that takes more than about twenty minutes.

Compositions, e.g., pharmaceutical compositions, nutritional compositions, medical foods, and food ingredients, as well as their methods of use, are provided, for treating diseases associated with hyperammonemia, e.g., urea cycle disorders (UCD) and hepatic encephalopathy (HE), e.g., minimal HE (MHE) and overt HE (OHE), and modulating enzyme activities and levels of microbes and taxa, and metabolites (e.g., ammonia) in the microbiome of a subject.

Disclosed are compositions comprising branched chain amino acids, urea cycle amino acids and essential amino acids for use in treating or preventing liver diseases and disorders with hyperammonemia ormuscle wasting in a subject.

A material which has excellent ammonia metabolism improving effect and is effective for endurance enhancement, anti-fatigue or the like is provided. An ammonia metabolism promoting agent, comprising catechins and ornithine as active ingredients. An endurance enhancing agent, comprising catechins and ornithine as active ingredients. An anti-fatigue agent, comprising catechins and ornithine as active ingredients. An agent for suppressing a reduction in blood glucose level by exercise, comprising catechins and ornithine as active ingredients. An agent for promoting recovery from reduced blood glucose level by exercise, comprising catechins and ornithine as active ingredients. An agent for suppressing a reduction in muscle glycogen by exercise, comprising catechins and ornithine as active ingredients. A muscle endurance enhancing agent, comprising catechins and ornithine as active ingredients. An agent for preventing or ameliorating hyperammonemia, hepatic encephalopathy or chronic fatigue syndrome, comprising catechins and ornithine as active ingredients.

Aspects of the disclosure relate to oligosaccharide compositions and methods of making the same. Also provided are methods of using oligosaccharide compositions as microbiome metabolic therapies for reducing ammonia levels and for the treatment of hyperammonemia-related diseases (e.g., urea cycle disorders and hepatic encephalopathy).

The invention discloses the application of L-arabinose to the preparation of medicine or health care products for preventing or curing hyperammonemia, and particularly discloses the application of L-arabinose to the preparation of medicine or health care products for reducing blood ammonia and/or endotoxin. The applicant finds, in experiments, that L-arabinose can effectively reduce the level of blood ammonia and endotoxin of a mouse (1 to 4 grams/kg/day), and body health is not damaged while the function is achieved.

The invention provides active salt of a dipeptide compound of ornithine and an aspartic acid, a preparation method of the active salt, a pharmaceutical composition including the active salt, and application of the dipeptide compound or the active salt thereof in preparation of medicine for preventing or treating hyperammonemia or liver diseases, in particular to hepatic encephalopathy. A test result clearly indicates that after the dipeptide compound of the ornithine and the aspartic acid and the active salt of the dipeptide compound are administered, the concentration of blood ammonia can beobviously reduced, and secondary memory disorder after TAA(tumor-associated antigen)-induced liver injury in rats can be obviously improved, indicating that the dipeptide compound and the active saltof the dipeptide compound have a certain treatment effect on hyperammonemia or liver diseases, in particular to the hepatic encephalopathy.

Provided herein are methods of treating a subject with hyperammonemia or a urea cycle disorder. The methods comprise administering to a subject in need thereof a therapeutic amount of a glucagon signaling pathway inhibitor, such that ammonia levels are lowered or that amino acid metabolism enzymes are down-regulated, or a condition or disease characterized by hyperammonemia is mediated, or at least one symptom or complication associated with the condition or disease is alleviated or reduced in severity. The glucagon signaling pathway inhibitor can be a small molecule inhibitor of the signaling pathway, an antisense inhibitor of the signaling pathway, shRNA, siRNA, a GCG neutralizing monoclonal antibody, a GCGR antagonist, a peptide inhibitor of the signaling pathway, a DARPin, a Spiegelmer, an aptamer, engineered Fn type-III domains, etc. The therapeutic methods are useful for treating a human suffering from hyperammonemia or a urea cycle disorder.

Embodiments of the present disclosure relate to doses of ornithine phenylacetate for use in treating or ameliorating hyperammonemia and methods of administering such doses of ornithine phenylacetate in patients suffering from chronic liver disease, such as cirrhosis. In some embodiments, the patient also has hepatic encephalopathy as a complication of the liver disease.

Some embodiments of the present application are directed to oral formulations of L-ornithine phenylacetate and methods of using the same. These oral formulations offer alternative administration routethan the standard intravenous administration of L-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, hepatic encephalopathy, or patients with urea cycle disorders.

The invention provides application of dihydroartemisinin in preparation of a medicine. The medicine is used for preventing or treating hyperammonemia. Therefore, a theoretical basis and application value are provided for human or animal hyperammonemia treatment or adjuvant therapy drugs.

A material which promotes ammonia metabolism in the body, as well as a material which has excellent ammonia metabolism improving effect and is effective for endurance enhancement and anti-fatigue are provided. An ammonia metabolism promoting agent, comprising catechins as an active ingredient. An agent for preventing or ameliorating hyperammonemia, hepatic encephalopathy or chronic fatigue syndrome, comprising catechins compound as an active ingredient. An ammonia metabolism promoting agent, an endurance enhancing agent and an anti-fatigue agent, comprising catechins, citrulline and arginine as active ingredients.